 | Up a level |
Plaimauer, B; Kremer Hovinga, J A; Juno, C; Wolfsegger, M J; Skalicky, S; Schmidt, M; Grillberger, L; Hasslacher, M; Knöbl, P; Ehrlich, H; Scheiflinger, F (2011). Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. Journal of thrombosis and haemostasis, 9(5), pp. 936-44. Oxford: Wiley-Blackwell 10.1111/j.1538-7836.2011.04224.x
Ferrari, S; Mudde, G C; Rieger, M; Veyradier, A; Kremer Hovinga, J A; Scheiflinger, F (2009). IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis, 7(10), pp. 1703-10. Oxford: Wiley-Blackwell 10.1111/j.1538-7836.2009.03568.x
Bergmann, I P; Kremer Hovinga, J A; Lämmle, B; Peter, H J; Schiemann, U (2008). Acute pancreatitis and thrombotic thrombocytopenic purpura. European journal of medical research, 13(10), pp. 481-2. München: I. Holzapfel
Tripodi, A; Peyvandi, F; Chantarangkul, V; Palla, R; Afrasiabi, A; Canciani, M T; Chung, D W; Ferrari, S; Fujimura, Y; Karimi, M; Kokame, K; Kremer Hovinga, J A; Lämmle, B; de Meyer, S F; Plaimauer, B; Vanhoorelbeke, K; Varadi, K; Mannucci, P M (2008). Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of thrombosis and haemostasis, 6(9), pp. 1534-41. Oxford: Blackwell 10.1111/j.1538-7836.2008.03099.x
Kremer Hovinga, J A; Zeerleder, S; Kessler, P; Romani de Wit, T; van Mourik, J A; Hack, C E; ten Cate, H; Reitsma, P H; Wuillemin, W A; Lämmle, B (2007). ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. Journal of thrombosis and haemostasis, 5(11), pp. 2284-90. Oxford: Blackwell 10.1111/j.1538-7836.2007.02743.x
Meyer, S C; Sulzer, I; Lämmle, B; Kremer Hovinga, J A (2007). Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. Journal of thrombosis and haemostasis, 5(4), pp. 866-7. Oxford: Blackwell 10.1111/j.1538-7836.2007.02438.x
Lämmle, B; Kremer Hovinga, J A (2006). A new tool to further explore the role of ADAMTS-13 in health and disease. Journal of thrombosis and haemostasis, 4(5), pp. 952-4. Oxford: Blackwell 10.1111/j.1538-7836.2006.01945.x
Fontana, S; Kremer Hovinga, J A; Lämmle, B; Mansouri Taleghani, B (2006). Treatment of thrombotic thrombocytopenic purpura. Vox sanguinis, 90(4), pp. 245-54. Oxford: Wiley-Blackwell 10.1111/j.1423-0410.2006.00747.x
Kremer Hovinga, J A; Mottini, M; Lämmle, B (2006). Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. Journal of thrombosis and haemostasis, 4(5), pp. 1146-8. Oxford: Blackwell 10.1111/j.1538-7836.2006.01904.x
Luken, B M; Kaijen, P H P; Turenhout, E A M; Kremer Hovinga, J A; van Mourik, J A; Fijnheer, R; Voorberg, J (2006). Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis, 4(11), pp. 2355-64. Oxford: Blackwell 10.1111/j.1538-7836.2006.02164.x
